Sex Hormone Influence on Tear Film Stability

Abstract

Sex hormones play a pivotal role in ocular surface homeostasis, with accumulating evidence linking hormonal fluctuations to alterations in tear film stability. This review synthesizes current scientific knowledge on the influence of estrogen, androgen, and progesterone on tear film composition, function, and clinical manifestations, integrating mechanistic insights and recent advancements. Clinically relevant implications for diagnosis, management, and future therapeutic strategies in hormone-related ocular surface disorders are discussed to inform practice and future research.

Introduction

Tear film stability is essential for maintaining optical clarity and protecting the ocular surface from desiccation and injury. Disruption of tear film homeostasis can lead to dry eye disease (DED), a prevalent condition with significant morbidity. Emerging research highlights the complex interplay between sex hormones and ocular surface integrity, with differences in prevalence and severity of DED among sexes suggesting a hormonal basis. This review examines the mechanisms by which sex hormones modulate tear film stability, the clinical consequences of hormonal dysregulation, and current approaches to diagnosis and management.

Epidemiology / Disease Burden

Dry eye disease affects approximately 5-34% of adults worldwide, with a higher incidence in women, particularly during periods of hormonal fluctuation such as menopause and pregnancy. Epidemiological studies consistently demonstrate that female sex is a risk factor for DED, implicating hormonal influence in disease pathogenesis. The burden of disease extends beyond discomfort, affecting visual function, daily activities, and quality of life. Increased healthcare utilization, work absenteeism, and substantial socioeconomic costs underscore the importance of understanding hormonal contributions to tear film instability.

Pathophysiology

The ocular surface and its adnexa are hormonally responsive tissues, expressing receptors for androgens, estrogens, and progesterone. Androgens have a trophic effect on the meibomian glands, promoting lipid layer stability and reducing evaporation. Estrogens and progesterone exert complex, sometimes antagonistic, effects; estrogens may increase inflammation and decrease lipid production, while progesterone can modulate immune responses. Hormonal imbalance or deficiency, as seen in menopause or androgen deprivation, disrupts tear film homeostasis by altering glandular secretion, mucin expression, and cytokine profiles, ultimately compromising tear stability.

Risk Factors

Key risk factors for hormone-related tear film instability include female sex, menopause, use of oral contraceptives, pregnancy, polycystic ovary syndrome (PCOS), and androgen deprivation therapy. Systemic conditions such as Sjögren\"s syndrome and autoimmune disorders are also associated with altered sex hormone levels and increased risk. Environmental factors, contact lens wear, and certain medications may exacerbate underlying hormonal susceptibilities, amplifying the risk of DED.

Clinical Features

Patients with hormone-related tear film instability commonly present with symptoms of dryness, grittiness, burning sensation, fluctuating vision, and ocular fatigue. Clinical examination may reveal reduced tear meniscus, conjunctival hyperemia, punctate epithelial erosions, meibomian gland dysfunction, and rapid tear film break-up time (TBUT). Symptoms often intensify during periods of hormonal change, such as perimenopause, postpartum, or with hormonal therapies, providing important diagnostic clues.

Diagnosis

Diagnosis is based on patient history, symptom questionnaires (e.g., OSDI), and objective assessments, including TBUT, Schirmer\"s test, ocular surface staining, and meibography. Hormone assays are not routinely performed but may be considered in complex or refractory cases. Identifying underlying hormonal influences is crucial for personalized management, particularly in women or individuals with relevant systemic conditions.

Treatment & Management

Management strategies are tailored to disease severity and underlying etiology. First-line therapy includes artificial tears, ocular lubricants, and environmental modifications. Addressing meibomian gland dysfunction with warm compresses and lid hygiene is essential. In hormone-driven cases, systemic hormone replacement therapy (HRT) remains controversial, with mixed evidence regarding efficacy and safety. Topical androgen formulations and omega-3 supplements show promise in enhancing tear film stability. Treating systemic conditions, optimizing hormonal balance, and minimizing exacerbating medications are important adjuncts.

Recent Advances / Emerging Therapies

Recent research has focused on the development of targeted therapies that modulate androgen and estrogen signaling at the ocular surface. Topical androgen analogs, selective estrogen receptor modulators (SERMs), and novel anti-inflammatory agents represent potential future interventions. Advances in tear proteomics and lipidomics have improved understanding of hormonal effects on tear composition, paving the way for personalized therapeutics. Additionally, non-pharmacological interventions such as intense pulsed light (IPL) therapy for meibomian gland dysfunction offer adjunctive benefits in select patients.

Guideline Recommendations

Contemporary guidelines emphasize a stepwise, individualized approach to DED management, incorporating patient education, environmental optimization, and tailored pharmacotherapy. Recognizing and addressing hormonal influences is critical, particularly in peri- and postmenopausal women, and in those receiving hormone-modulating therapies. Multidisciplinary collaboration with endocrinologists or gynecologists may be warranted in complex cases. Regular follow-up and patient-reported outcome measures are recommended to monitor therapeutic response.

Conclusion

The influence of sex hormones on tear film stability is increasingly recognized as a key factor in the pathogenesis and management of dry eye disease. Understanding hormone-driven mechanisms provides valuable insights for the diagnosis, risk stratification, and individualized treatment of affected patients. Ongoing research into hormone-targeted therapies and biomarkers holds promise for improving outcomes in this prevalent and impactful condition.